Pre-clinical study.
Agree it is undervalued, however AGN is several years ahead on the clinical timeline - having completed a phase 1 and started dosing in a placebo-controlled double-blind phase 2. Plus ODD designation for HIE. I'd argue that AGN is also undervalued.
Pre-clinical study.Agree it is undervalued, however AGN is...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.66M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7780 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 12462 | 2 |
View Market Depth
| Last trade - 16.12pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.7¢ |
Change
0.000 ( 3.08 %) |
||||
| Open | High | Low | Volume | ||
| 6.7¢ | 6.8¢ | 6.6¢ | 157839 | ||
| Last updated 15.44pm 17/05/2024 ? | |||||
| NYR (ASX) Chart |
Day chart unavailable